共 3 条
- [3] Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial CANCER MEDICINE, 2020, 9 (24): : 9419 - 9430